UCLB
VC Fund
London, United Kingdom
UCLB is a VC fund in London focused on Biotechnology and Health Care. UCLB is the commercialisation company of UCL and its partner NHS Trusts. They bring to market truly world-leading, world-changing technologies, innovations that have a real and positive impact on people’s lives. UCLB the access point to the wealth of innovation and intellectual property emanating from UCL and partner hospitals including UniversityCollege Hospital, Great Ormond Street Hospital, Royal Free Hospital and Moorfields Eye Hospital. They offer a number of services to assist the technology development process, from consultancy through to collaborative research, IP licensing and the creation of spinout companies and joint ventures to maximise the commercial potential of new discoveries, materials and processes.
- Total investments:
- 33
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries UCLB invests in
Stages UCLB invests in
Countries UCLB invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $259k–$17M
- Series A
- $2M–$12M
Investment Focus
Industry
- Biotechnology 12 (36%)
- Health Care 10 (30%)
- Medical 6 (18%)
- Software 6 (18%)
- Therapeutics 6 (18%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Richard Fagan
Director of BioPharm
|
Director of BioPharm | Total investments: 0 | Find email | |
Anne Lane
Interim Managing Director
|
Interim Managing Director | Total investments: 0 | Find email | |
Marina Santilli
Associate Director (Physical Sciences & Engineering)
|
Associate Director (Physical Sciences & Engineering) | Total investments: 2 | Find email | |
Simon Goldman
Investment Director
|
Investment Director | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Panda Surgical is a medical equipment manufacturing company that offers surgical instruments accompanied by AI-powered software. | $1.3M / Seed / Oct 05, 2025 | ||
| Gigaton is a climate technology company developing artificial intelligence to decarbonize energy-intensive industries. It intends to use AI technology to reduce carbon emissions by gigatonnes per year. Its emphasis is on energy-intensive industries like cement, steel, and glass, which account for more than 20% of global emissions. Deep learning isused by Carbon Re's Delta Zero platform for industrial decarbonization to enable rapid development and deployment of new low-carbon industrial processes, designs, and materials. | $1.4M / Pre-Seed / Oct 20, 2021 | ||
| Astroscreen protects brands and defends democracy from harmful social media manipulation campaigns also known as astroturfing. | $1M / Seed / Apr 18, 2019 | ||
| Data has never been more valuable. But with growing privacy demands and tightening regulations, most of the world’s data is locked away and unusable.For businesses to make better decisions, develop new technologies and deliver more value for customers, they need data they can actually use. They need to set their data free to do more. Hazy ispioneering the new data. We’re the world’s leading synthetic data company, re-engineering enterprise data so that it can be: - Shared without restrictions - data that can move freely, without restriction, to where it’s needed most in businesses and society - Used without limits - data that’s reliable, safe and easy for people and businesses to use to solve problems and create new value. - Trusted without question - data that’s open, transparent and trusted by people, businesses and society. | $1.8M / Seed / May 02, 2018 | ||
| Correvate was formed to commercialise a technology that enables the automatic alignment and subsequent analysis of 3D point cloud datasets. The technology was initially created in the Department of Electronic and Electrical Engineering at University College London and then, on 1st January 2018, exclusively licensed to Correvate. It has since beenenhanced by both Correvate and UCL into the Vercator® product suite www.vercator.com Vercator software provides fast, robust point cloud processing to enable automated 3D understanding of the environment.The technology can be applied to 3D point cloud datasets created using any scanning technology of any wavelength. Correvate’s first market sector is in construction – where professionals such as surveyors, architects and construction engineers create a ‘digital twin’ of the target project, yielding improvements in productivity well-recognised both by the professionals themselves and by the grant-giving teams in the UK’s Department of Business, Energy and Industrial Strategy. | Seed / Jan 01, 2018 | ||
| Intrinsic Semiconductor Technologies is established to developed silicon-oxide based RRAM technologies. Intrinsic's technology is fully air stable and inherently CMOS compatible. Intrinsic's core technology can be configured as non-volatile memory, multilevel memory, hardware acceleration for Machine Learning, and neuromorphic devices. | Seed / Jan 01, 2018 | ||
| Autolus Therapeutics is working on next-generation programmed T cell treatments for the treatment of cancer. The company's pipeline includes Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Autolus was established in 2014 by Tim Funnell and Martin Pule in London, England. | $80M / Series C / Sep 26, 2017 | ||
| Intract Pharma Limited is an oral drug delivery licensing and product development company offering a range of proprietary formulation technologies to deliver novel and optimised therapeutics targeted to patient needs. The company is a spin-out of University College London, and is centred around over 15 years of research and innovation from thelaboratory of Professor Abdul Basit. Intract's range of formulation technologies includes Phloral™ for colon targeted delivery, and ProRelease™, a versatile microparticulate delivery system. Complementary to these, Intract has developed unique gastrointestinal (GI) models, which closely reflect the physiological environment of the human GI tract, enabling accurate and predictable in vitro-in vivo correlation. | Seed / Jan 01, 2017 | ||
Appredict
|
Appredict Ltd is a data analysis company that specialises in analysing and understanding the development lifecycle of apps and providing this information to app developers to help them maximise the revenue streams from their products. | Seed / Jan 01, 2017 | |
| Apollo Therapeutics is a collaborative venture between three world-leading UK universities (Imperial College London, University College London and the University of Cambridge) and three global pharmaceutical companies (AstraZeneca, GlaxoSmithKline, Johnson & Johnson Innovation). It provides committed translational funding and drug discoveryexpertise for novel therapeutics, sourced from the best of British academic research, accelerating them towards the clinic.Apollo’s unique model provides quick, independent access to the resources to grow innovations and to champion the best of British academic research to industry. Apollo’s experienced team of industry scientists have a proven track record of therapeutic delivery and work in partnership with academics and industry partners, crafting each bespoke project to optimise the chances of long-term success. Apollo Therapeutics aims to create the therapies of the future by partnering with the UK’s globally leading academic science base and UK based Pharma industry to have a real impact on patient treatments and outcomes. | Seed / Jan 01, 2017 | ||
| See all 33 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does UCLB invest in?
UCLB invests primarily in Biotechnology, Health Care and Medical startups, most often at Seed and Series A stage. Most of the 33 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is UCLB's check size?
UCLB typically joins rounds of $259k–$17M at Seed and $2M–$12M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds UCLB participates in.
How do I contact UCLB?
Public channels for UCLB include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at UCLB?
The team at UCLB includes Richard Fagan (Director of BioPharm), Anne Lane (Interim Managing Director) and Marina Santilli (Associate Director (Physical Sciences & Engineering)). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
